Micron Biomedical’s Post

We have just published our second quarter 2024 Business Update and financial results. With effective execution and on track towards our 2024 milestones, we continue making significant progress across our three-pronged business model focusing on Targets, Pipeline, and Responders.   Since our last quarterly release, several partnership discussions are ongoing as we further advance our multi-partner approach. Moreover positive Phase 2 immune data on our lead asset, EVX-01, was presented at ASCO and 67% Objective Response Rate (ORR) from Phase 1 published in leading medical journal . As we prepare for the upcoming Phase 2 one-year clinical data readout at ESMO Congress 2024, we remain focused on delivering solid progress in this program.   On the technology front, our AI-Immunology™ platform continues to strengthen, showcased by the improved performance of key components presented at a recent computational biology conference. This is also supported by the encouraging positive feedback by the World Intellectual Property Organization's on our patent application for an AI-Immunology™ driven novel cancer target identification method.   We remain dedicated to advancing our pipeline and business development discussions. With our current cash position, we remain funded into February 2025.   You can find the full Q2 2024 Business Update here: https://lnkd.in/dfYzpWAE   #Evaxion #Biotech #AIImmunology #CancerResearch #Innovation

Listen up structural biologists and drug discovery experts! We are thrilled to announce a significant breakthrough at Cube Biotech! Leveraging just one of our newest copolymer inventions in our NativeMP™ Platform, we have successfully obtained the very first structure of the ‘Human’ P2X4 membrane protein in its native membrane environment via cryo-EM. P2X4, a crucial player in synaptic transmission and inflammation, holds significant promise in drug discovery, particularly for developing novel therapies for chronic pain and inflammatory diseases. Traditionally, detergents have been the standard method for stabilizing membrane proteins for cryo-EM. However, they fall short of preserving the protein’s native environment, affecting functional stability and further analysis (Schmidpeter et al., 2022 https://lnkd.in/etCdXuSv; Corradi et al., 2018 https://lnkd.in/eA5K2aHQ). Our Next Generation Copolymers – AASTYs, Ultrasolute™ Amphipols, and our newest invention, Ultrasolute™ Cubipol – address this challenge by stabilizing membrane proteins in their native environment in a single step. This enhances the functional stability of these proteins and makes them suitable for sensitive downstream applications like cryo-EM. Stay tuned for the upcoming launch, where we will unveil the full lineup of the new copolymers joining our Next Generation Copolymers. Get ready to explore how these innovative solutions can revolutionize your research and drug discovery efforts! #CryoEM #MembraneProteins #DrugDiscovery #BiotechInnovation #P2X4 #ScientificBreakthrough #CubeBiotech 

Make the challenging membrane protein targets of your drug discovery pipeline accessible with our NativeMP™ Platform! Our new copolymer inventions used in our NativeMP™ Platform, we retain our targets in its native membrane environment and thereby stabilize them as protein-lipid-copolymer complexes with superb thermo- and colloidal stability. This will enable you to run your downstream applications without any limitation. It holds true for structure determination by cryo-EM but also for your in vitro assays, phage display screenings or DEL screenings, where one needs good performing membrane proteins. Join us and be part of the change, how to address membrane protein research as well as drug discovery differently! #CryoEM #MembraneProteins #DrugDiscovery #BiotechInnovation #ScientificBreakthrough #CubeBiotech

🌟 𝗘𝘅𝗰𝗶𝘁𝗶𝗻𝗴 𝗕𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵! 🌟 Congrats to the whole team, Dr. Philipp T. Hanisch and Felipe Merino! Just to give you some insights, the sample - 𝗿𝗲𝗮𝗱𝘆 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗰𝗿𝘆𝗼 𝗴𝗿𝗶𝗱 - was 𝗼𝗯𝘁𝗮𝗶𝗻𝗲𝗱 𝘄𝗶𝘁𝗵𝗶𝗻 𝗹𝗲𝘀𝘀 𝘁𝗵𝗮𝗻 𝟮 𝘄𝗲𝗲𝗸𝘀 and done by a newcomer. This process would typically take years! Stay tuned for the launch of our full copolymer lineup. Discover how these cutting-edge tools can revolutionize your research and drug discovery! #Biotechnology #ProteinStabilization #ResearchInnovation #LifeSciences #MembraneProteins #CubeBiotech

🌟 Exciting News for #BIO2024! 🌟 Dynamk Capital is thrilled to announce that Vernal Biosciences, one of our innovative portfolio companies, is exhibiting at the BIO 2024 conference! 🎉 At Dynamk Capital, we believe in empowering groundbreaking biotech companies that are shaping the future of healthcare. Vernal Biosciences is at the forefront of RNA synthesis technology, driving advancements in therapeutics and diagnostics. Their presence at BIO 2024 underscores the critical role they play in the biotech ecosystem. Here’s why this is important: 🔬 Innovation Showcase: Vernal Biosciences will highlight their cutting-edge RNA synthesis capabilities, providing insights into how their technology is revolutionizing the biotech industry. 🤝 Networking Opportunities: BIO 2024 is a premier event for the life sciences sector, offering unparalleled networking opportunities with industry leaders, investors, and potential partners. 🌍 Global Impact: By exhibiting at BIO 2024, Vernal Biosciences is positioned to expand their global reach and accelerate their mission to deliver transformative RNA-based solutions. We are proud to support Vernal Biosciences as they pave the way for the next generation of biotech innovations. Visit their booth at BIO 2024 and discover how they are making a difference in the world of life sciences! #BIO2024 #Biotech #Innovation #RNATechnology #DynamkCapital #VernalBiosciences #HealthcareInnovation

“Mecwins Expands Global Reach with Innovative Biotech Services”   Mecwins is pleased to announce its expansion into the global market with the launch of its cutting-edge biotech services, which will be available to clients worldwide. "Following the provision of biotech services to R&D centres and other partner companies, we are now offering our services to the wider global market," stated the company, highlighting its readiness to share its expertise beyond its established network. This strategic move is a response to the increasing demand for high-precision solutions in the biotech sector. Mecwins has built a strong reputation for providing innovative, reliable, and scalable services that are tailored to the specific needs of research institutions and biotech companies. By offering its advanced capabilities in immunoassay development and nanoparticles on a global scale, Mecwins aims to accelerate breakthroughs in areas such as diagnostics, drug discovery, and advanced materials. This expansion reflects the company's commitment to driving scientific innovation and supporting the international R&D community. Mecwins invites researchers, institutions, and companies worldwide to collaborate and explore the transformative potential of its cutting-edge technologies as it enters this new chapter. Further information about the company's services can be found at https://lnkd.in/dvEt6jZ9 or by contacting the team directly. #Mecwins #MecwinsServices #Biotech

ClexBio has secured investments from GG 1978 and EQT Foundation, with additional contributions from our existing investor base, to accelerate development of our tissue bioengineering platform and emerging portfolio of tissue therapeutic products.   This marks a significant milestone for ClexBio and is a testament to the breakthrough innovation behind the technologies that power our tissue bioengineering platform, and their potential to transform the future of human health.   A huge thank you to our amazing team for their hard work, to our existing investor base for their ongoing support, and to both GG 1978 and EQT Foundation for believing in our vision to develop the next generation of tissue therapeutics that can restore cell functions lost to chronic degenerative diseases. Read more here: https://lnkd.in/dKJy99tM #Biotech #Innovation #Funding #TissueTherapeutics #LifeSciences #VentureCapital

🤩 We’re thrilled to announce Evercyte’s latest collaboration with Singapore-based AIM Biotech, marking a major step forward in advancing Organ-on-a-Chip (OOAC) technology! This partnership unites Evercyte's expertise in creating telomerized cell lines with AIM Biotech's cutting-edge OOAC technology, offering unparalleled benefits for drug screening, disease research, and beyond. Our contributions include: 🔬 𝗛𝘂𝗺𝗮𝗻 𝗨𝗺𝗯𝗶𝗹𝗶𝗰𝗮𝗹 𝗩𝗲𝗶𝗻 𝗘𝗻𝗱𝗼𝘁𝗵𝗲𝗹𝗶𝗮𝗹 𝗖𝗲𝗹𝗹𝘀 (𝗛𝗨𝗩𝗘𝗖/𝗧𝗘𝗥𝗧𝟮) - Ideal for bioassays in angiogenesis and wound healing research. 🫁 𝗛𝘂𝗺𝗮𝗻 𝗟𝘂𝗻𝗴 𝗙𝗶𝗯𝗿𝗼𝗯𝗹𝗮𝘀𝘁 𝗖𝗲𝗹𝗹𝘀 (𝗟𝗙/𝗧𝗘𝗥𝗧𝟯𝟬𝟵) - Perfect for studying pulmonary function, airway inflammation, and disease modeling. With this collaboration, we are moving towards replacing animal models with humanized in vitro models, accelerating the discovery of safe, effective medicines while addressing ethical and predictive challenges in drug development. Read the PR ➡️ https://lnkd.in/dgvib6aY #Evercyte #AIMBiotech #DrugDiscovery #OrganOnAChip #TelomerizedCells #InVitroModels

In this short movie, you can clearly observe the microstreaming flow around the microbubbles. I invite you to watch and listen carefully. 🎤Presenter: Professor Ayache Bouakaz ⏱️In Scientific session Non-ionising radiation: Ultrasound-mediated drug delivery Title: Recent advances in ultrasound-mediated drug delivery: Insights from preclinical and clinical trials. #MicrostreamingFlow #Microbubbles #UltrasoundMechanics #DrugDelivery #ScientificSession #UltrasoundResearch #ClinicalTrials

It's true what you've been hearing through the grapevine: Aarhus is the birthplace of many of the most promising new biotech companies 🌱 The renowned biotech industry media Labiotech.eu confirms this with its ranking of '10 European biotech companies likely to make a big splash in the biotech sector'. On the list, you’ll find two spinouts from Aarhus Universitet – Draupnir Bio and ComMIT Biologics. Draupnir Bio is a spinout from Health - Aarhus University – Aarhus University, founded in 2017, developing new treatments to transform the management of heart disease. ComMIT Biologics is a spinout from Faculty of Natural Sciences - Aarhus University, founded in 2023, developing immunotherapies for the treatment of cancer, among other things. This recognition is a huge pat on the back for the two companies, their founders, and their employees – and it’s also an acknowledgment of Aarhus University and the research and development environment we have here in this city 🏆🌍 See the full list and read more about the different biotech-companies on it👇 The Kitchen - AU Erhverv og Innovation Aarhus University Technology Transfer.